Skip to main content
. 2022 Apr 30;34(2):95–108. doi: 10.21147/j.issn.1000-9604.2022.02.04

Figure 3.

Figure 3

Comparison of PFS and OS curves in CTCMUC1+ and CTCMUC1− patients. (A) Median PFS of CTCMUC1+ and CTCMUC1− patients was 35.0 and 45.0 months, respectively, but there was no statistical difference (HR=1.242; 95% CI: 0.787−1.959; P=0.357); (B) OS of CTCMUC1+ patients tended to be significantly shorter than CTCMUC1− patients (HR=1.900; 95% CI: 1.020−3.540; P=0.043). PFS, progression-free survival; OS, overall survival; CTC, circulating tumor cell; HR, hazard ratio; 95% CI, 95% confidence interval.